To Contact our Research Team
Call 204.787.4701 or 204.787.1643
Email ibdresearch@exchange.hsc.mb.ca
Crohn’s Disease
Etrolizumab (Beta 7)
-
Nonresponder or been intolerant to steroids, immunosuppressives or anti-TNF
-
No prior use of Entyvio
-
2:1 Etro (high and low dose) to placebo
-
Subcutaneous
-
Responders are re-randomized at week 14 to placebo or low dose Etro
-
If nonresponder, can roll over into Open Label for 52 weeks
Gusulkumab (IL23) and Ustekinumab (IL12/23)
-
Naïve or nonresponder to TNF
-
5:1 drug and placebo
-
Induction (0,4,8) IV then subcut for up to 44 weeks
-
Placebo non-responders receive Ustekinumab for 24 weeks
PF-06651600 (JAK3) and PF-06700841(TYK2)
-
Naïve or non responder to TNF
-
2:1 drug and placebo.
-
ORAL
-
After 12 wks, everyone receives drug for 52 weeks total
Ulcerative Colitis
ABI-M201 (Probiotic) with patients on Mesalamine in mild-moderate UC
-
Must show inadequate response to mesalamine >4 weeks
-
Cohort A 1:1 Cohort B 3:1 (20 subjects each cohort)
-
8 weeks
-
ORAL
Pancreas Divisum
-
Randomized trial of ERCP with minor papilla endoscopic sphincterotomy (miES) for treatment of recurrent acute pancreatitis
-
Must have had an acute pancreatitis attack within 24 months plus one other attack prior
Surveillance for first-degree relatives of Crohn’s Disease
-
Screening first degree relatives of Crohn’s disease patients using capsule endoscopy
-
Undergo blood test, questionnaires and patent capsule endoscopy
-
Once reviewed, a capsule endoscopy done. If any signs of CD, colonoscopy scheduled.